ClinicalTrials.gg
CompletedNCT06254274Updated Oct 26, 2026

A Study of RAY1225 in Participants With Type 2 Diabetes

A Phase 2 interventional study of RAY1225 and Placebo in T2DM (Type 2 Diabetes Mellitus), sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
356th of 767
210 · median 199
Started
2024
with 82 others
Phase 2
61 of 909
14 open now
Registered
638th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 356th largest by enrollment of the 767 interventional ones that give a count, is one of 83 that started in 2024, is one of 61 in phase 2, and was the 638th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Type 2 diabetes had been diagnosed for at least 12 weeks prior to screening and one of the following conditions:

    1. have T2DM controlled with diet and exercise alone;
    2. are stable in dose and type on a single or in a combination of oral antidiabetic medication, metformin, α-glucosidase inhibitors or SGLT-2 inhibitors only ,within 12 weeks before screening;
  2. ≥ 20 kg/m²;
  3. Fasting blood-glucose(FPG)\<15 mmol/L;
  4. Weight change \< 5% in the 12 weeks before screening;
  5. Participants (including partners) must use reliable methods of during the study and until 6 months following the last dose of product.

Exclusion criteria

Exclusion Criteria:

  1. have type 1 diabetes mellitus;
  2. Severe diabetic complications, including proliferative retinopathy or maculopathy, severe diabetic neuropathy (e.g., urinary retention, urinary incontinence, and painful peripheral neuropathy), resting tachycardia, orthostatic hypotension, intermittent claudication, or diabetic foot;
  3. Two or more episodes of ketoacidosis, lactic acidosis, or hyperosmolar state leading to hospitalization within 24 weeks before screening;
  4. had grade 3 hypoglycemic events within 12 months before screening,
  5. Three or more grade 2 hypoglycemic events occurred within 3 months before screening;
  6. Have symptoms related to hypoglycemia at screening;
  7. Within 6 weeks before screening, serious trauma, serious infection, or surgery that may have affected glycemic control was reported;
  8. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered by the investigator.
  9. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    RAY1225 (cohort 1)

    Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.

    Drug: RAY1225

  • Placebo comparator
    Placebo (cohort 1)

    Participants received Placebo administered SC once two weeks for 24 weeks.

    Drug: Placebo

  • Experimental
    RAY1225 (cohort 2)

    Escalating doses of RAY1225 administered subcutaneously (SC) once two week

    Drug: RAY1225

  • Placebo comparator
    Placebo (cohort 2)

    Participants received Placebo administered SC once two week

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A.

    Time frame: Baseline,Week 24

Secondary outcomes

  1. Percentage of Participants With HbA1c Target Value of <6.5%

    Time frame: Baseline,Week24

  2. Percentage of Participants With HbA1c Target Value of <7%

    Time frame: Baseline,Week24

  3. Percentage of Participants With HbA1c Target Value of <5.7%

    Time frame: Baseline,Week24

  4. Change From Baseline in Fasting Serum Glucose

    Time frame: Baseline,Week24

07

Study locations

1 site
  • Peking University People's Hospital
    Beijingcun, Hebei, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 16 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2025 → Jul 2025 and completion Dec 2025 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2024
First posted
Feb 12, 2024
StartActual
Feb 26, 2024
Primary completionActual
Jul 20, 2025was Dec 2025
CompletionActual
Sep 8, 2025was Dec 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 26, 2026
Primary completion
Dec 20, 2025→Jul 20, 2025 (actual)
Oct 26, 2026
Study completion
Dec 20, 2025→Sep 8, 2025 (actual)
Oct 26, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange From Baseline in Hemoglobin A1c (HbA1c)Baseline,Week 26 → Baseline,Week 24
Oct 26, 2026
Secondary outcomes
4 time frame changed
What changed in the outcomes
  • Time framePercentage of Participants With HbA1c Target Value of <6.5%Baseline,Week26 → Baseline,Week24
  • Time framePercentage of Participants With HbA1c Target Value of <7%Baseline,Week26 → Baseline,Week24
  • Time framePercentage of Participants With HbA1c Target Value of <5.7%Baseline,Week26 → Baseline,Week24
  • Time frameChange From Baseline in Fasting Serum GlucoseBaseline,Week26 → Baseline,Week24
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Active, not recruiting→Completed
    Primary completion Dec 20, 2025→Jul 20, 2025 (now actual)
    Study completion Dec 20, 2025→Sep 8, 2025 (now actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange From Baseline in Hemoglobin A1c (HbA1c)Baseline,Week 26 → Baseline,Week 24
    Secondary outcomes 4 time frame changed
    What changed in the outcomes
    • Time framePercentage of Participants With HbA1c Target Value of <6.5%Baseline,Week26 → Baseline,Week24
    • Time framePercentage of Participants With HbA1c Target Value of <7%Baseline,Week26 → Baseline,Week24
    • Time framePercentage of Participants With HbA1c Target Value of <5.7%Baseline,Week26 → Baseline,Week24
    • Time frameChange From Baseline in Fasting Serum GlucoseBaseline,Week26 → Baseline,Week24
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06254274
Responsible party
Sponsor
First posted
Feb 12, 2024
Start date
Feb 26, 2024
Primary completion
Jul 20, 2025
Completion
Sep 8, 2025
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilpatide

Start the discussion